New Manufacturing Process Patent for Ox-1

Theracryf PLC

16 April 2026

 

16 April 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1

Additional patent submission provides potential 20-year protection
Strengthens long-term commercial value and partnering potential

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that it has filed a new process patent covering novel aspects of the manufacturing method for its lead programme, a selective orexin-1 receptor antagonist (Ox-1) being developed for addiction.

The patent, when granted, will protect for 20 years from filing, potentially to 2046, extends the commercial exclusivity for the Ox-1 blocker across major markets, substantially beyond the life of the existing global Composition of Matter patent. The filing follows recent successful manufacturing optimisation and scale-up work during which several novel and efficiency-enhancing chemical process improvements were identified.

Process patents provide an additional barrier to generic competition, as alternative manufacturing routes must be developed to avoid infringement, which are typically not undertaken by competitors. The filing builds on the Company's recently announced strengthening of the Ox-1 patent estate across key global markets and forms part of its broader strategy to establish a robust intellectual property portfolio as the programme advances towards completing the data required for clinical readiness later in 2026.

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

"This new process patent submission further strengthens the intellectual property protection surrounding our lead asset and has the potential to extend its commercial exclusivity very substantially.

As TheraCryf progresses swiftly towards clinical development, expanding our broad and defensible patent portfolio is central to maximising the long-term commercial value of the programme and its attractiveness to potential partners."

-Ends-

Enquiries

TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO	[phone] [e-mail]
Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Patrick Weaver	[phone]
Turner Pope Investments (Joint Broker) Guy McDougall / Andy Thacker	[phone]
Northstar Communications (Investor Relations) Sarah Hollins	[phone] [e-mail]

About TheraCryf

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders.

The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.

For further information, visit: https://theracryf.com

 

END